- Meet like-minded leaders, visionaries and regulators
- Stay ahead with insights into current & emerging industry trends
- Fuel business growth by gaining invaluable BFSI insights
- Discover potential collaborations and partnerships

Dear Esteemed Delegates,
On behalf of Indian Association for Cell and Gene Therapy (IACGT), it is our great pleasure to welcome you to the 1st IACGT Annual Meeting , to be held from 25th to 27th September 2026 in Bengaluru.
IACGT is a pioneering community dedicated to advancing the transformative potential of cell and gene therapies (CGT). IACGT is a professional membership organization uniting clinicians, scientists, researchers, and industry leaders across India to drive innovation and collaboration in this rapidly evolving field.
The annual meet brings together physicians, scientists, researchers, scholars, and healthcare professionals from across India to share knowledge, exchange ideas, and foster collaboration. This unique platform highlights the latest advancements in cell and gene therapy, enabling participants to engage with thought leaders and explore emerging trends shaping the future of medicine.
By uniting leading experts and emerging voices across disciplines, the event offers a dynamic environment for knowledge exchange, advancing clinical practice, and contributing to the development of cell and gene therapies in India.
We look forward to welcoming you in person for an engaging and inspiring scientific experience in Bengaluru.
Welcome to the Indian Association for Cell and Gene Therapy (IACGT), a pioneering community dedicated to advancing the transformative potential of cell and gene therapies (CGT). We are a professional membership organization uniting clinicians, scientists, researchers, and industry leaders across India to drive innovation and collaboration in this rapidly evolving field.
IACGT aims to be a catalyst for transformative change in healthcare, advancing cell and gene therapies as the cornerstone of precision medicine. We envision a future where tailored treatments based on individual genetic profiles become the global standard of care. Through collaboration across research, clinical, and industry sectors, we strive to accelerate the development and application of innovative therapies for previously untreatable diseases.














